Investment bank Leerink Partners recently released a research report, initiating coverage on biotechnology company Satellos Bioscience Inc. (stock symbol: MSLE) for the first time.

Investment bank Leerink Partners has initiated coverage on Satellos Bioscience Inc. (MSLE) with an “Outperform” rating and a $20 target price. This positive outlook by analysts highlights the biotechnology company’s innovative technology platform. The report aims to provide professional research references for investors interested in Satellos Bioscience.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin